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ABSTRACT:Cardiacdysfunctiondevelopsduring sepsis inhumans and rodents. In themodelofpolymicrobial sepsis
induced by cecal ligation and puncture (CLP), we investigated the role of the NLRP3 inflammasome in the heart.
Mouseheart homogenates from sham-proceduremice containedhighmRNA levels ofNLRP3 and IL-1b. Using the
inflammasome protocol, exposure of cardiomyocytes (CMs) to LPS followed by ATP or nigericin caused release of
mature IL-1b. Immunostaining of left ventricular frozen sections before and 8 h after CLP revealed the presence of
NLRP3 and IL-1b proteins inCMs.CLP caused substantial increases inmRNAs for IL-1b andNLRP3 inCMswhich
are reduced in the absence of either C5aR1 or C5aR2. After CLP, NLRP32/2mice showed reduced plasma levels of
IL-1b andIL-6. Invitroexposureofwild-typeCMs to recombinantC5a (rC5a) causedelevations inbothcytosolicand
nuclear/mitochondrial reactive oxygen species (ROS),whichwereC5a-receptor dependent. Use of a selectiveNOX2
inhibitor prevented increased cytosolic and nuclear/mitochondrial ROS levels and release of IL-1b. Finally,
NLRP32/2mice had reduceddefects in echo/Doppler parameters in heart afterCLP. These studies establish that the
NLRP3 inflammasomecontributes to the cardiomyopathyofpolymicrobial sepsis.—Kalbitz,M., Fattahi, F.,Grailer,
J. J., Jajou, L., Malan, E. A., Zetoune, F. S., Huber-Lang, M., Russell, M. W., Ward, P. A. Complement-induced
activation of the cardiac NLRP3 inflammasome in sepsis. FASEB J. 30, 3997–4006 (2016). www.fasebj.org
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Over the past decade, the nucleotide-binding oligomeri-
zation domain–like receptorwith pyrin domain (NLRP)-3
inflammasome has received a great deal of attention as an
important mediator pathway of the innate immune sys-
tem. It contains 3 components [NLRP3, caspase-1 and
apoptosis-associated speck-like protein containing a cas-
pase recruitment domain (ASC)]. Inflammasome activa-
tion byLPS (primer) followedbyATP (activator) results in
caspase-1 activation, which causes cleavage of precursor
forms of IL-1b and -18 into mature (cleaved) active
cytokines that are then secreted. The chief products of
the NLRP3 inflammasome, IL-1b, and -18, are strongly
proinflammatory (1, 2). Other priming agents include
intrinsic factors [danger-associated molecular patterns
(DAMPs)], such as uric acid crystals, hyaluronan, amyloid
fibrils, cholesterol crystals, and histones, which are re-
leased from damaged or inflamed tissues and from neu-
trophil extracellular traps (NETs) activated by C5a (3),
resulting in NLRP3 inflammasome activation, damaging
inflammatory responses that amplify tissue and organ
damage (4–6). Furthermore, pathogen-associated molec-
ular patterns (PAMPs) activate TLRs and the NLRP3
inflammasome (7, 8).Alternative activating agents include
bacterial toxins (nigericin andmaitotoxin) (9).Collectively,
the NLRP3 inflammasome can provide protective re-
sponses in infectious and noninfectious situations, but
excessive inflammasome activation often intensifies
inflammatory injury.
During remodeling after myocardial ischemia and
reperfusion, activation of the NLRP3 inflammasome in
cardiac fibroblasts has been observed (10, 11), which was
largely prevented in the absence of ASC or caspase-1 (11).
As a consequence of events in the ischemic heart, release of
proinflammatory mediators has been postulated to am-
plify myocardial injury (12, 13). Blockade of caspase-1 (12,
14), overexpressionof IL-1Rantagonist (15), or blockadeof
IL-1b with neutralizing antibody (16) have resulted in
ABBREVIATIONS: ASC, apoptosis associated speck-like protein containing
a caspase recruitment domain; CLP, cecal ligation and puncture; C5a,
complement component 5a; C5aR1, complement component 5a receptor 1;
CM, cardiomyocyte; CO, cardiac output; DAMP, danger-associated mo-
lecular pattern; echo, echocardiography; E9sa, peak velocity from the
septal annulus of the mitral valve; HR, heart rate; IL-1R, IL-1 receptor;
KO, knockout; LV, left ventricle; NET, neutrophil extracellular trap; NOX,
NADPH oxidase; NLRP3, nucleotide-binding oligomerization domain-
like receptor with pyrin domain 3; PAMP, pathogen-associated molecular
pattern; qPCR, quantitative real time PCR; rC5a, recombinant comple-
ment component 5a; ROS, reactive oxygen species; SV, stroke volume;
VolS, volume at end systole; VolD, volume at end diastole
1 Correspondence: University of Michigan Medical School, Department of
Pathology, 1301 Catherine Rd., 7520 MSRB I, Box 5602, Ann Arbor, MI
48109-5602, USA. E-mail: pward@umich.edu
doi: 10.1096/fj.201600728R
0892-6638/16/0030-3997 © FASEB 3997
protective effects in myocardial ischemia. In essence, in
the ischemic heart tissue, proinflammatory products from
NLRP3 inflammasomeactivation intensified cardiac injury.
After experimental burn trauma and during experi-
mental cecal ligation and puncture (CLP), cardiomyocytes
(CMs) have been shown to generate and release proin-
flammatory cytokines, such as TNF, IL-1b, and IL-6 (17,
18). CMs exposed in vitro to the complement anaphyla-
toxin C5a likewise release IL-1b and TNF (18). NLRP3
inflammasome activation was found to be essential in
complement-mediated IL-1b release in murine dendritic
cells (19) and human retinal pigment epithelial cells (20).
Cytokines and C5a have both been shown to have car-
diosuppressive effects (17, 21–23). Further, in vitro addi-
tion of C5a to rat CMs isolated from both sham-procedure
and CLP animals causes dramatic cardiac dysfunction in-
volving both contractility and relaxation (23) associated
withoverexpressionofC5a receptor (C5aR) inCMs isolated
after CLP (23). Furthermore, in experimental CLP sepsis,
complement C5a receptor 1–knockout (KO) (C5aR12/2)
and C5a receptor 2–KO (C5aR22/2) mice had survival
rates superior to those of wild-type (WT) mice (24). C5a
blockade or absence of either C5a receptor (C5aR1 or
C5aR2) diminished development of cardiac dysfunction
after thermal injury (25) orduringexperimental sepsis (26),
respectively.
However,whetherNLRP3 inflammasome activation in
CMs during sepsis plays a role in development of cardiac
dysfunction after sepsis and its precise relation to the C5a
receptors are not clear. The current experiments provide
novel evidence for the constitutive presence andactivation
of the NLRP3 inflammasome in CMs during poly-
microbial sepsis in mice. The events are associated with




CMswere isolated from young adult rats andmice, according to
published procedures (3, 18, 27, 28). In brief, after excision of the
heart, the aorta ascendens was cannulated, and the hearts were
fixed to a Langendorff perfusion system. The hearts were retro-
grade perfusedwith Liberase solution (Hoffmann-La Roche,
Mannheim, Germany), according to the manufacturer’s di-
rections. After digestion, the heart was detached from the
Langendorff apparatus; atria and vessels were removed, and
the ventricles were cut into small pieces, which were gently
triturated with a plastic transfer pipette. After isolation of the
CMs, the Ca2+ concentration in the buffer fluid was gradually
increased in 6 steps (to 1.8 mM) and the cells were cultured in
M199 medium with 1% insulin-transferrin-selenium-X
(Thermo Fisher Scientific, Waltham, MA, USA) including
antibiotic-antimycotic (Thermo Fisher Scientific).
Animals and anesthesia
All procedures conformed to the Guide for the Care and Use of
Laboratory Animals (National Institutes of Health, Bethesda, MD,
USA). The study was approved by the University Committee
on Use and Care of Animals and performed according to the
guidelines. Specific pathogen-free male Sprague-Dawley rats
(300–350 g; Harlan Laboratories, Indianapolis, IN, USA) and
male C57BL/6 mice (6–10 wk, 25–30 g; The Jackson Laboratory,
Bar Harbor, ME, USA) were anesthetized with the combination
of ketamine (40 mg/kg body weight; Hospira, Lake Forest, IL,
USA) and xylazine (5 mg/kg body weight; Lloyd Laboratories,
Shenandoah, IA,USA) intraperitoneally. Someexperimentswere
also performed using male C57BL/6 mice from our C5aR12/2
and C5aR22/2 breeding colonies at the University of Michigan.
The generation of C5aR12/2 and C5aR22/2mice on a C57BL/6
background has been described previously (29, 30). Male
NLRP32/2mice were purchased from The Jackson Laboratory.
Experimental sepsis
Sepsiswas inducedby theCLPprocedure, asdescribedpreviously
(31). In anesthetized animals, amidline surgical incisionwasmade,
and the cecumwas exposed and ligated at half the distance between
the distal pole and the base of the cecum, resulting in a midgrade
sepsis (32). The cecum was punctured, and a small amount of
feces was expressed. The abdomenwas closed in layers with 5-0
sutures (Ethicon, Inc., Somerville, NJ, USA). Sham-procedure
animals underwent the sameprocedure, includingmanipulation
of the bowel in the absence of CLP. In all animals, 3.0 ml (rats) or
1.0 ml (mice) fluid resuscitation (lactated Ringers solution) was
injectedgiven subcutaneously in the nuchal region, after surgery.
Fluids were given immediately (0 h) and 12 h after CLP. The
animals were euthanized 8, 12, 16, 18, 24, or 48 h after CLP.
Measurement of ROS
Intracellular ROS in rat CMs was measured by flow cytometry
using CellRox dyes (Thermo Fisher Scientific) according to the
manufacturer’s directions. The dyes detect either cytoplasmic or
mitochondrial ROS. A minimum of 10,000 events was observed
on a BD LSR II flow cytometer (BD Biosciences) and analyzed
with FlowJo Software 7.6.4 (Tree Star, Ashland, OR, USA). Dot
plots and figures show$10,000 events.
Confocal imaging
For confocal imaging, CMs were cultured on sterile glass slides
coated with natural mouse laminin (Thermo Fisher Scientific)
stained with CellRox Deep Red or Deep Green Reagent. These
dyes are cell and mitochondrion permeable. NLRP3 and IL-1b
staining was performed on mouse frozen left ventricle (LV) tis-
sue sections. ForNLRP3 stainingmonoclonal rat anti-mousewas
used as primary (R&D Systems, Inc., Minneapolis, MN, USA)
and donkey anti-rat (AF-647) as secondary antibody (Jackson
ImmunoResearch Laboratories, West Grove, PA, USA). For
IL-1b staining, rabbit anti-mouse antibody was used as primary
(Abcam, Inc., Cambridge, MA, USA) and donkey anti-rabbit
(AF-488) as secondary antibody (Jackson ImmunoResearch Lab-
oratories). After staining, cells/sections were washed twice with
PBS and coveredwith ProLongGoldAntifade Reagent (Thermo
Fisher Scientific). Confocal imaging was performed by the LSM
510 Confocal microscope (Zeiss, Thornwood, NY, USA) in the
Microscopy and Image-Analysis Laboratory (Department of
Cell and Developmental Biology, University of Michigan
Medical School).
IL-6 and IL-1b ELISA
Supernatants of cultured rat CMs were collected and analyzed
using ELISA kits (R&D Systems) to measure IL-1b. In some ex-
periments, blood fromWT andNLRP32/2micewas collected
3998 Vol. 30 December 2016 KALBITZ ET AL.The FASEB Journal x www.fasebj.org
through cardiac puncture using anticoagulant citrate dextrose
solution at different time points after CLP, and the plasma was
analyzed using ELISA kits (R&D Systems) to measure IL-6 and
mature IL-1b according to the manufacturer’s instructions.
NLRP3, caspase-1 and IL-1b in mouse heart
homogenates and CMs by RT-PCR
Mouse hearts (isolation as described above) were obtained after
CLPor the shamprocedure andharvested at various times. Total
RNA was isolated by the Trizol method (Thermo Fisher Scien-
tific) according to the manufacturer’s instructions. RNA was
obtained and amplified (SYBR) using reagents from Thermo
Fisher Scientific. RT-PCR amplificationwas performed on a 7500
Real-Time PCR System (Thermo Fisher Scientific). Calculation of
the relative quantitative results was performed according to the
22DDCt algorithm.
The following mouse primers were used: NLRP3 59GCTG-
CTCAGCTCTGACCTCT39 (fwd), mouse NLRP3 59-AGGTGA-
GGCTGCAGTTGTCT-39 (rev); IL-1b 59-TGAAAGCTCTCCA-
CCTCAATGGAC-39 (fwd), IL-1b 59-TGCAGCCATCTTTAGG-
AAGACACG-39 (rev); caspase-1 59-CCAGAGCACAAGACTT-
CTGAC-39 (fwd), caspase-1 59-TGGTGTTGAAGAGCAGAA-
AGC-39 (rev); mouse ASC-1 59-GCAATGTGCTGACTGA-
AGGA-39 (fwd), mouse ASC-1 59-TGTTCCAGGTCTGTCAC-
CAA-39 (rev). For the housekeeping gene, 59-CTTCAACAG-
CAACTCCCACTCTTCC-39 (fwd), Gapdh 59-GGTGGTCCA-
GGGTTTCTTACTCC-39 (rev) was used.
Reagents
The following reagentswereused: recombinant rat ormouseC5a
(rC5a) with virtually no detectable LPS were produced as has
been described (23, 33). Chemicals used for preparation of solu-
tions for CM isolation; VAS-2870, used as an NADPH oxidase
(NOX)-2 inhibitor; and Y-VAD as a global caspase-1 inhibitor
were purchased from Sigma-Aldrich (St. Louis, MO, USA). In-
hibitors were used in concentrations of 10 mM according to the
literature.
Echocardiography
Echocardiography (echo) was performed as published (34).
All echocardiograms were recorded by a registered echocardi-
ographer who was blinded to mouse genotype. NLRP32/2
mice, together with WT C57Bl/6J mice, were weighed and
anesthetized with inhaled isoflurane. Imaging was performed
with a Vevo 770 High-Resolution In Vivo Imaging System
(VisualSonics, Inc., Toronto, ON, Canada) equipped with an
RMV-707, 30 MHz (Real-Time Visualization; up to 45 MHz)
scanhead. LV volume at end systole (VolS) and volume at end
diastole (VolD) were measured from the parasternal long-axis
view at the level of the tips of the leaflets of the mitral valve at
end systole and enddiastole, respectively, andused to calculate
stroke volume (SV) and ejection fraction (EF): SV = VolD 2
VolS and EF % = endocardial SV/endocardial VolD 3 100.
Cardiac output (CO) was calculated from SV and heart rate
(HR): CO = SV 3 HR. Mitral valve E and A wave inflow ve-
locities were sampled at the tips of the leaflets of the mitral
valve from the apical 4-chamber view. Doppler tissue imaging
was performed with acquisition of peak velocity (E9) from the
lateral annulus (E9la) and septal annulus (E9sa) of the mitral
valve, imaged from the apical 4-chamber view. Isovolumic
relaxation time, from the closure of the aortic valve to the
opening of the mitral valve, was measured from the apical
5-chamber view using Doppler flow imaging. Imaging was
performed at 8 h after CLP.
Statistical analysis
For statistical analysis, Prism 6 (GraphPad, La Jolla, CA,
USA) was used. All values are expressed as means 6 SEM.
Data were analyzed by 1-way ANOVA followed by Dunnett’s
multiple-comparison test. For comparison of 2 groups, the
Student’s t test was used. Values of P # 0.05 were considered
significant.
RESULTS
Levels of inflammasome components and
IL-1b in LV homogenates and responses of
CMs to inflammasome protocols
qRT-PCR technology was used with mouse LV homoge-
nates (Fig. 1A) tomeasure inflammasomecontent (mRNAs
for the 3 inflammasome components: NLRP3, caspase-1,
andASC) and IL-1b in resting cells. Resultswere expressed
as a ratio to Gapdh mRNA, which was set at a value
of 1.0. In LV homogenates from normal WT mouse
hearts, the declining order of subunit content (mRNAs)
was NLRP3 . caspase-1 = IL-1b . ASC. We used an
Figure 1. mRNA levels of inﬂammasome components in mouse heart homogenates and activation of NLRP3 inﬂammasome in
CMs. A) Using LV homogenates from mouse hearts, mRNAs were measured for NLRP3, caspase-1, ASC, and IL-1b by qRT-PCR
and developed as a ratio to mRNA for Gapdh (set as 1.0). B) Mouse CMs were incubated with buffer or with LPS (1 mg/ml for 4 h
at 37°C) or the combination, with the endpoint being IL-1b release. C, D) CM release of IL-1b was measured after cell exposure
to buffer or LPS (primer), followed by addition of activator (ATP or nigericin, 1 mM or 10 mm, respectively, for 45 min at 37°C).
Where indicated, 10 mm Y-VAD, a global caspase inhibitor, was also used. For each bar, n $ 5 samples. *P , 0.05
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inflammasome protocol with the endpoint being release
of mature IL-1b from rat CMs. CMs were exposed to
buffer or to LPS for 4 h at 37°C (Fig. 1B), or they were
exposed to the inflammasome activators ATP (1 mM)
(Fig. 1B) or nigericin (10mM) (Fig. 1C) for 45min at 37°C.
The ATP or nigericin caused release of IL-1b, same as
baseline levels. Baseline levels of IL-1b were;20 pg/ml.
The presence of LPS alone was associated with doubling
of IL-1b release from CMs compared to baseline release
(Fig. 1B). When CMs were exposed to ATP or nigericin
after incubationwith LPS, IL-1b release fromCMs rose to
80 pg/ml, indicating activation of NLRP3 inflammasome
in CMs (Fig. 1B, C). In Fig. 1D, baseline levels of IL-1b
release was small (;30 pg/ml), whereas the presence of
C5a alone resulted in doubling the amount of IL-1b re-
leased (;50 pg/ml). The presence of LPS followed by
nigericin caused greatly enhanced release of IL-1b, to
;180 pg/ml,whereas the initial presence ofC5awith LPS
followed by nigericin caused a synergistic release of IL-1b
(380 pg/ml), suggesting a synergy in inflammasome ac-
tivation when the initial priming agents were LPS+C5a,
followed by nigericin as the activator agent. When the
same conditions were used in the continuing presence of
the pancaspase inhibitor, Y-VAD (10 mM), the release of
IL-1b fell by 52%.
Activation of the NLRP3 inflammasome in LV
CMs from CLP mice
We used immunofluorescence confocal microscopy to
search for the NLRP3 inflammasome in frozen sections
from the LVs of mouse hearts before (Fig. 2, ctrl sham) or
8 h after CLP (Fig. 2; magnification,363). Selection of the
8-h timepoint afterCLPwasbasedonourknowledge that,
at this time, echo/Doppler parameters indicated the onset
of cardiac dysfunction after sepsis (3). LV frozen sections
from sham-procedure hearts revealed very faint amounts
of IL-1b or NLRP3 protein, as detected by immunofluo-
rescence (Fig. 2, ctrl sham). However, there was a greatly
increasedpresenceof IL-1b andNLRP3protein inLVCMs
from WT CLP hearts, as indicated by the green (IL-1b) or
red (NLRP3) fluorescence, respectively. The presence of red
fluorescence, denotingNLRP3protein, occurred in apattern
similar to that for IL-1b. DAPI yieldedblue-stainednuclei in
CMs. The merge image produced a yellow fluorescence
(coalescence of green and red colors), togetherwith the blue
nuclei that were clearly within the CMs, all of which were
prominent in frozen longitudinalLVsections.Lowerpower
images were obtained to determine whether NLRP3 pro-
tein was detectable in interstitial areas of the heart. Such
evidence could not be found.
In sepsis, NLRP3 inflammasome activation in
mouse CMs is reduced in absence of either
C5aR1 or C5aR2
Mouse LV CMs were isolated before (control) or 8 to 16 h
after polymicrobial sepsis from WT, C5aR12/2, and
C5aR22/2 mice (Fig. 3). CMs were then evaluated for
changes in mRNAs for components of the NLRP3
inflammasome and IL-1b. mRNAs for NLRP3, caspase-1,
ASC, IL-1b, andGapdhwerequantitatedbyqRT-PCRand
expressed as ratios to Gapdh in the same specimens. The
fold change in sham-procedure heart was compared to
Gapdh, which was set at 1.0 (not shown). There was an
;35-fold increase inmRNAforNLRP3 inCMs8–16hafter
sepsis (Fig. 3A). These increases were almost totally ab-
lated in CMs from septic C5aR12/2 or C5aR22/2 mice.
Therewerevery small elevations (,1.5-fold) inLVmRNAs
for caspase-1 after CLP (Fig. 3B). The slightly diminished
increments for caspase-1 mRNAs in LV CMs from mice
lacking either C5a receptor were not statistically different.
Thepattern for changes inASCmRNAwasvery small and
not statistically significant (Fig. 3C). LV mRNA for IL-1b
rose nearly 80-fold 8 h after CLP in WT mice (Fig. 3D).
Virtuallyno increase inmRNAfor IL-1bwas found inmice
lacking either C5a receptors.
Absence of NLRP3 in CLP mice affects both
IL-1b and IL-6 proteins
AfterCLP,we assessedplasma levels of IL-1b (as amarker
of inflammasome activation) and IL-6, which is another
heart-suppressive cytokine (Fig. 4). We determined the
Figure 2. Activation of NLRP3 inﬂammasome in
LV mouse CMs after CLP. Immunoﬂuorescence
analysis of LV frozen sections from sham-procedure
cointrol (ctrl sham) mouse WT heart (left boxes)
or hearts 8 h after CLP. Magniﬁcation, 363.
Analysis involved immunostaining for IL-1b
(green), NLRP3 (red), nuclear staining by DAPI,
and the merge image for all 3 stains. Staining for
IL-1b and NLRP3 was very faint in sham-
procedure control hearts, in striking contrast
to hearts 8 h after CLP.
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appearance of IL-1b in plasma fromWTmice and found a
sustained increase in IL-1b over the period of 8–24 h after
CLP, although there was a pattern of gradual reduction of
plasma IL-1b 18–24 h after CLP (Fig. 4A). We selected the
18-h interval after CLP in WT and NLRP32/2mice for ad-
ditional experiments. Therewas a 75% reduction for plasma
IL-1bwhencompared to the levels of IL-1b inWTCLPmice
(Fig. 4B). When plasma IL-6was alsomeasured inWTCLP
mice, there was a gradual decline in plasma IL-6 at 12, 18,
and24hafterCLP (Fig. 4C). Forplasma IL-6, the 8-h interval
afterCLPwas selected, usingWTandNLRP3-KOmice.The
NLRP3-KO mice showed a 58% reduction in plasma IL-6
(Fig. 4D). It was clear that the absence of NLRP3 resulted in
reduced plasma levels of both IL-1b and -6 after CLP.
Complement-dependent in vitro and in vivo
induction of ROS in CMs
Fluorescent dyes were used that have been verified to
distinguish between ROS in a nuclear/mitochondrial lo-
cation and a cytosolic location (Fig. 5). In this series of
experiments, confocal fluorescence microscopy was used
Figure 3. In sepsis, NLRP3 inﬂammasome activation in mouse CMs is reduced in absence of either C5aR1 or C5aR2. Activation of
the NLRP3 inﬂammasome components NLRP3 (A), caspase-1 (B), and ASC (C), as well as IL-b (D), in mouse CMs before (not
shown) and 16 h after CLP. In these studies, qRT-PCR was used in LV heart homogenates fromWT, and C5aR12/2 or C5aR22/2,
16 h after CLP. Results are ratios of NLRP3 inﬂammasome component mRNA to Gapdh mRNA (the latter being set at 1.0). For
each bar, n $ 4 samples. *P , 0.05.
Figure 4. Reduced plasma cytokines in NLRP32/2mice after CLP. Plasma levels of IL-1b (A, B) after CLP were reduced in NLRP3 8–24 h
after CLP. A) Time course of plasma levels of IL-1b after CLP. B) Plasma levels of IL-1b were obtained 18 h after CLP. C, D) A similar
protocol was used with a focus on plasma IL-6 8 h after CLP. All assays were performed by ELISA. For each bar, n $ 5 plasma samples.
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on rat CMs before (Fig. 5A, B) and after (Fig. 5C, D) CM
exposure to rC5a (1 mg/ml) at 37°C for the indicated pe-
riods of time. The fluorescent dyes are cell permeable. The
CMs had been preloadedwith 2 fluorochromes: the green
dye (CellRox Green Reagent), which detects nuclear and
mitochondrial ROS, and the red dye (CellRoxDeep Red)
which detects cytosolic ROS. (See Material and Methods
for details.) Endpoints were obtained by confocal micros-
copy (Fig. 5A–D) or by flow cytometry of isolated CMs
(Fig. 5E–L). Before CM exposure to C5a, very low levels of
nuclear and mitochondrial ROS staining (green) were
found (Fig. 5A) and ROS levels of staining (red) in the
cytosol (Fig. 5B) were barely detectable. In striking con-
trast,whenCMswere exposed in vitro to rC5a (1mg/ml for
30 min) at the indicated time points, there was diffuse
green staining for nuclear/mitochondrial ROS (Fig. 5C)
and moderately intense red staining for cytosolic ROS
(Fig. 5D). ROS in cytosolic and nuclear/mitochondrial
areas was assessed with fluorogenic dyes in CMs ex-
posed in vitro to C5a or in CMs at different time points after
CLP (Fig. 5E–H). CMs were exposed to C5a (1 mg/ml) for
10–90minat37°C, resulting inatime-dependentprogressive
increase in cytosolic (Fig. 5E) and nuclear/mitochondrial
ROS (Fig. 5F). Cytosol and nuclear/mitochondrial ROS
buildup was assessed as a function of the amount of C5a
used for 30 min at 37°C (Fig. 5G, H). Cytosolic ROS (Fig.
5G) was similar at the 3 concentrations of C5a used,
whereas nuclear/mitochondrial ROS was found in CMs
only at the highest concentration of C5a used (Fig. 5H).
Buildup of cytosolic and nuclear/mitochondrial ROS in
CMs as a function of time after CLP showed an ROS
buildup 8–24 h after CLP, followed by decline 48 h after
CLP (Fig. 5I, J). Mice (WT, C5aR12/2, and C5aR22/2)
were subjected to polymicrobial sepsis and 18 h later, and
their CMswere evaluated by flow cytometry for cytosolic
and nuclear/mitochondrial ROS (Fig. 5K, L). In both lo-
cales, there was evidence of C5aR involvement. Buildup
of cytosolic ROS required both C5a receptors (Fig. 5K),
whereas buildup of ROS in a nuclear/mitochondrial loca-
tion appeared to be more closely linked to C5aR1 (Fig. 5L).
Reduced C5a-induced ROS and IL-1b in CMs in
the presence of an NOX2 inhibitor
Asexpected, exposure of rat CMs toC5a (1mg/ml) caused
statistically significant increases in cytosolic (Fig. 6A) and
Figure 5. Buildup of ROS in nuclear/mitochondrial and cytosolic areas of CMs. Fluorescent dyes that detect ROS in
mitochondria/nuclei (B, D, F, H, J, L) or in cytosol (A, C, E, G, I, K) of rat CMs were used, with endpoints being ﬂuorescence in
CMs, as determined by confocal microscopy. A, B) Sham-procedure CMs exposed to buffer. C, D) CMs exposed to rC5a (1 mg/ml
for 30 min). E, F) CMs exposed to C5a 10, 30, and 90 min. G, H) CMs exposed to increasing amounts of C5a for 90 min. I, J ) CMs
from WT mice obtained at various time points after CLP. K, L) CMs obtained from WT, C5aR12/2, and C5aR22/2 mice 16 h
after CLP. For each bar, n . 5 samples. *P , 0.05.
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nuclear/mitochondrial (Fig. 6B) ROS, as detected by flow
cytometry and by release of IL-1b (Fig. 6C). The presence
of the NOX2 inhibitor totally suppressed the buildup of
cytosolic and nuclear/mitochondrial ROS in CMs. The
presence of the NOX2 inhibitor also prevented release of
IL-1b from C5a-activated CMs (Fig. 6C).
Effects of absence of NLRP3 on sepsis-induced
echo/Doppler defects
Selected measures of systolic and diastolic heart function
were obtained in mice before and 8 h after CLP (Fig. 7).
Both WT and NLRP32/2mice were used. In WT mice, a
significant decrease in HR was noted by 8 h after CLP
compared to sham-procedure controls (Fig. 7A).However,
the mild reduction in HR noted in the NLRP32/2mice at
8 h after CLP was not statistically significant when com-
pared to sham-procedure NLRP32/2 mice. LV SVs were
also better preserved in the NLRP32/2 mice after CLP
compared to WT (Fig. 7B). The higher HR and higher
SV resulted in a trend toward a higher (calculated) CO in
the NLRP32/2 mice compared to WT at 8 h after CLP
(Fig. 7C), although the increase did not reach statistical
significance. However, the VolS values were also signifi-
cantly higher in the NLRP32/2mice than in the WT con-
trols 8 h after CLP, again more closely approximating the
LV systolic volume noted in the sham-procedure animals
(Fig. 7D).
As in our previous studies (3, 26), CLP resulted in
a significant reduction in LV volumes (Fig. 7B, D, E), a
modest reduction in diastolic function (Fig. 7F–H), and a
modest increase in systolic function, as measured by LV
ejection and shortening fraction 8 h after CLP (data not
shown). For each diastolic measure [mitral E/A ratio (Fig.
7F), isovolumic relaxation time (Fig. 7G), and E/E9sa (Fig.
7H)], there was a trend toward better diastolic function in
the NLRP32/2mice compared to controls after CLP, but
the differences did not reach statistical significance. In the
WT mice, significant differences developed after sepsis,
but not in the NLRP32/2 group in the case of isovolumic
relaxation time and E/E9sa data. Again, the most sub-
stantial cardiovascular effects ofCLPwere reduction in the
Figure 6. NOX2 inhibitor blocks buildup of ROS in CMs and release of IL-1b. A, B) Cytosolic ROS (A) and nuclear/
mitochondrial ROS (B) in absence or presence of NOX2 inhibitor in rat CMs exposed to C5a for 1 h at 37°C. C) Companion
studies focused on IL-1b release from C5a-activated CMs in the presence or absence of NOX2 inhibitor. CMs exposed to C5a for
8 h. For each bar, n $ 4 samples. *P , 0.05.
Figure 7. ECHO/Doppler parameters in WT and NLRP32/2 mice 8 h after CLP. HR (A), LV SV (B), CO (C), LV VolS (D), LV
VolD (E), E/A ratio (F), isovolumic relaxation (G), and E/E9sa (H) represent selected measures of systolic and diastolic heart
function in mice before and 8 h after CLP. For each bar, n = 5 mice. ns, nonsigniﬁcant. *P , 0.05.
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VolS and VolD, despite fluid resuscitation. At 8 h post-
CLP, there was a marked reduction in VolS and VolD,
whichwas less pronounced in theNLRP32/2mice than in
the WT controls (Fig. 7D, E).
DISCUSSION
NLRP3 inflammasome activation in CMs has been de-
scribed during viral myocarditis after coxsackievirus B3
infection (35). Inhibition of inflammasome activation with
a pan-caspase-1 inhibitor resulted in reduced intensity of
myocardial injury in this model along with improved
cardiac function. In mice, LPS infusion or in vitro presence
of LPS with CMs was also associated with myocardial
dysfunction (36). In cardiac fibroblasts, the NLRP3 inflam-
masomewas up-regulated in the presence of LPS, inwhich
caspase-1 was activated and IL-1b release occurred (37). In
an earlier study, exposure to LPS for 24 h resulted in IL-1b
secretion from cardiac fibroblasts, but not from CMs (11).
NLRP3 inflammasome activation in various cell types
in vivoand invitrohasoftenbeenassociatedwithTLR2and
-4 binding of DAMPs and PAMPs (38, 39) in which IL-1b
was released from monocytes and macrophages after
stimulationwith aTLR2 or -4 ligand, especiallywhenATP
was used as a secondary stimulus (activator) (9, 40). In
macrophages, NLRP3 inflammasome priming with LPS,
followed by activation caused by ATP or nigericin neces-
sitated the availability of the purinergic P2X7 receptor and
was accompanied with depletion of cytosolic K+, in-
dicating activation of Na+/K+-ATPase (9, 41). ATP has
also been found to cause transient pore formation in the
cell membrane via pannexin-1, allowing DAMPs to cross
the plasma membrane and directly activate the NLRP3
inflammasome in the fetus (41). Accordingly, for the cur-
rent studies, we induced in vitro inflammasome model
(LPS followed by ATP or nigericin) for inflammasome
activation in CMs, resulting in activation of the NLRP3
inflammasome and robust IL-1b release (Fig. 1).
The sublytic membrane attack complex of complement
has been found to trigger intracellular Ca2+ fluxes, leading
to NLRP3 inflammasome activation and loss of the mito-
chondrial trans-membrane potential and activation of
caspase-1, resulting in IL-1b release from primary human
lung epithelial cells (42) and from murine dendritic cells
(19). In human monocytes, C5a in combination with TNF
has been shown to prime for cholesterol crystal-induced
IL-1b releaseby increasing IL-1b transcripts andactivation
of caspase-1 (43)accompaniedbyC3aR(byC3a)activation
which induced IL-1b release by increasing pannexin-1-
mediated ATP efflux into the extracellular space (44). C5a
was found to prime human retinal pigment epithelial cells
for inflammasome activation by lipofuscin-mediated
photooxidative damage (20). Further, in earlier studies of
rat CMs, IL-1b release was found to be complement de-
pendent (18). In the current report, there was a more than
40-fold increase in NLRP3 and IL-1b mRNA expression
during CLP-induced sepsis, which was reduced in the
absence of either C5aR1 or -2 (Fig. 3), indicating an acti-
vation route forNLRP3 inflammasome inCMs. This result
is in linewith our immunofluorescent stainingdata (Fig. 2)
indicating that polymicrobial sepsis caused buildup of IL-
1b and NLRP3 protein in CMs, which was not present in
mice lacking either C5a receptor. Together, these data are
consistent with the conclusion that polymicrobial sepsis
causes upregulation of the NLRP3 inflammasome (pre-
dominately involvingNLRP3and IL-1bmRNAs) inmouse
CMs in a manner that requires both C5a receptors. This
upregulation may contribute to the harmful events
linked to the cardiomyopathyof sepsis. In general,where
activation of the NLRP3 inflammasome in the heart has
been documented, most studies have associated such
events in myocardial fibroblasts and in granulation tis-
sue (containing neutrophils and macrophages) after
ischemic–reperfusion injury (45). We documented that,
under certain conditions, the NLRP3 inflammasome can
be activated in LV CMs and ultimately linked to release
of extracellular histones, which have been shown to
cause cardiac dysfunction (3). Our recent experiments
also showed that plasma extracellular histones were di-
minished in mice lacking NLRP3 or C5a receptors (3).
Such data suggest that theNLRP3 pathway regulates other
pathways that lead to NET formation.
Our results suggested that absence of NLRP3 reduced
both NLRP3-related cytokines (IL-1b) and non-NLRP3-
associated IL-6 (Fig. 4). Becausewehavepreviously shown
invitro thatC5a-activatedCMsreleaseTNF, IL-1b, and IL-6
from CLP mice or rats, each of which is known to be car-
diosuppressive (18), the reduced level of IL-6 inNLRP32/2
mice may suggest that the NLRP3 inflammasome is in-
volved inCMactivation that affects releaseof IL-1b, aswell
as IL-6 and TNF. The tertiary structure of NLRP3 con-
taining a highly conserved disulfide bond connecting the
pyrin domain is very sensitive to altered redox states (46).
In the current study,we focused on the ability of C5a to
activate theNLRP3 inflammasome. ThebuildupofROS in
CMs after in vitro exposure to C5a, aswell as after onset of
CLP (Fig. 5), indicates a redox imbalance indicative of an
oxidative state. Recent studies suggest that CMs exposed
to C5a generate ROS from at least 2 different sources
(mitochondrial oxidases and cytosolic NOX2) (47). These
results suggest that, after CLP, ROS in both cytosolic and
nuclear/mitochondrial locales depend on C5a together
with the C5a receptors. In CMs, ROS were increased in
both locales in the presence ofC5a or during sepsis (Fig. 5).
Cytosolic ROS buildup in CMs during heart failure has
been linked to activation of cytosolic NOX2 (48, 49). Fur-
thermore,NLRP3was colocalized inmitochondria (42, 50).
After inhibition ofmitochondrial complex I and III, ROS in
mitochondria were increased, together with NLRP3 acti-
vation (51, 52). In the present study in CMs, cytosolic and
nuclear/mitochondrial ROS generation in response to C5a
was attenuated by the NOX2 inhibitor, accompanied by
decreased IL-1b release (Fig. 6), suggesting that the NOX2
inhibitor has multiple blocking effects on signaling path-
ways. (53–55). The results of the present study are in ac-
cordance with those in studies showing that inhibition
of NADPH oxidase-derived ROS prevents ATP-induced
caspase-1 activation and IL-1b release in alveolar macro-
phages (56). Our findings identify a novel physiologic
posttranslational mechanism in the control of NLRP3
inflammasome-mediated inflammatory response in CMs.
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The cardiovascular effects of polymicrobial sepsis ap-
pear to be significantly reduced in NLRP32/2mice com-
paredwith effects inWTmice, suggesting that theNLRP3
inflammasome mediates some of the effects of sepsis on
cardiovascular performance. The effects may be due to a
reduction in third-space fluid losses and intravascular
volume depletion after CLP. There may also be direct
myocardial effects, as noted by a trend toward an im-
provement in diastolic function (Fig. 7). Together, these
data indicate that absence of NLRP3 confers protective
effects in cardiovascular compromise after sepsis. Our re-
sults are in accordance with earlier studies showing that
inhibition of NLRP3 inflammasome by glyburide treat-
ment in mice prevents myocardial dysfunction and re-
duced levels of plasma IL-1b, together with improved
myocardial contractile function in septic mice (37).
In summary, the activated NLRP3 inflammasome is a
critical regulator of cardiomyopathy in sepsis. Targeting
NLRP3 to attenuate the C5a-induced cardiomyopathy of
sepsis may be a feasible therapeutic strategy.
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